NASDAQ:ENTO - US33749P4081 - Common Stock
The current stock price of ENTO is 2.7 USD. In the past month the price increased by 131.36%. In the past year, price increased by 127.85%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.07 | 375.50B | ||
AMGN | AMGEN INC | 13.01 | 152.70B | ||
GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.99 | 40.63B | ||
INSM | INSMED INC | N/A | 30.67B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
NTRA | NATERA INC | N/A | 23.06B | ||
BIIB | BIOGEN INC | 8.79 | 20.62B |
Entero Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
ENTERO THERAPEUTICS INC
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
Employees: 2
Phone: 15615897020
The current stock price of ENTO is 2.7 USD. The price increased by 1.89% in the last trading session.
The exchange symbol of ENTERO THERAPEUTICS INC is ENTO and it is listed on the Nasdaq exchange.
ENTO stock is listed on the Nasdaq exchange.
ENTERO THERAPEUTICS INC (ENTO) has a market capitalization of 4.29M USD. This makes ENTO a Nano Cap stock.
ENTERO THERAPEUTICS INC (ENTO) currently has 2 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ENTO does not pay a dividend.
ENTERO THERAPEUTICS INC (ENTO) will report earnings on 2025-10-20.
ChartMill assigns a technical rating of 10 / 10 to ENTO. When comparing the yearly performance of all stocks, ENTO is one of the better performing stocks in the market, outperforming 96.46% of all stocks.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |